Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis

被引:21
|
作者
Evangelopoulos, Maria Eleftheria [1 ]
Koutsis, Georgios [1 ]
Markianos, Manolis [1 ]
机构
[1] Univ Athens, Eginit Hosp, Sch Med, Dept Neurol, 74 Vassilisis Sophias Ave, Athens 11528, Greece
关键词
D O I
10.1155/2014/486282
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several studies have investigated leptin levels in patients with multiple sclerosis (MS) with somewhat conflicting results. They have all focused on patients with established relapsing-remitting (RR) MS but have not specifically looked at patients with clinically isolated syndrome (CIS) suggestive of MS, in the early stages of disease. In this study, serum leptin levels were measured in 89 treatment-naive patients with CIS (53 patients) or RRMS (36 patients) and 73 controls searching for differences between the groups and for associations with several disease parameters. The expected significant sexual dimorphism in leptin levels (higher levels in females) was observed in both MS patients and controls. Increased leptin levels were found in female patients with RRMS compared to female controls (P = .003) and female CIS patients (P = .001). Female CIS patients had comparable levels to controls. Leptin levels correlated positively to disease duration, but not to EDSS, in female patients with RRMS. The results of the present study do not indicate involvement of leptin in the early stages of MS. Normal leptin levels in patients with CIS suggest that leptin does not have a pathogenic role. The ratio leptin/BMI increases during disease course in female MS patients in a time-dependent and disability-independent manner.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Uric acid serum levels in patients with relapsing-remitting multiple sclerosis in Iran
    Ashtari, F.
    Aghaei, M.
    Bahar, M. A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S63 - S63
  • [22] Expression of apoptosis-related genes in relapsing-remitting multiple sclerosis and clinically isolated syndrome
    Hagman, S.
    Caliskan, R.
    Helminen, M.
    Dastidar, P.
    Elovaara, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 349 - 349
  • [23] Expression of apoptosis-related genes in relapsing-remitting multiple sclerosis and clinically isolated syndrome
    Hagman, S.
    Caliskan, R.
    Helminen, M.
    Dastidar, P.
    Elovaara, I.
    JOURNAL OF NEUROLOGY, 2014, 261 : S236 - S236
  • [24] Expression of apoptosis-related genes in blood of clinically isolated syndrome and relapsing-remitting multiple sclerosis patients
    Sanna, Rinta
    Raunio, Minna
    Irina, Elovaara
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 10 - 10
  • [25] Interferon β therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis
    Sena, A.
    Pedrosa, R.
    Ferret-Sena, V.
    Cascais, M. J.
    Roque, R.
    Araujo, C.
    Couderc, R.
    MULTIPLE SCLEROSIS, 2008, 14 (06): : 857 - 859
  • [26] Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis
    Niiranen, Marja
    Kontkanen, Aleksi
    Jaaskelainen, Olli
    Tertsunen, Hanna-Mari
    Selander, Tuomas
    Hartikainen, Paivi
    Huber, Nadine
    Solje, Eino
    Haapasalo, Annakaisa
    Kokkola, Tarja
    Lohioja, Tarja
    Herukka, Sanna-Kaisa
    Simula, Sakari
    Remes, Anne M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
  • [27] Consensus of opinion of US neurologists on practice patterns in clinically isolated syndrome and relapsing-remitting multiple sclerosis
    Tornatore, C.
    Phillips, J.
    Khan, O.
    Miller, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S283 - S283
  • [28] Benefit-Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis
    Qizilbash, Nawab
    Mendez, Ignacio
    Sanchez-de la Rosa, Rainel
    CLINICAL THERAPEUTICS, 2012, 34 (01) : 159 - 176
  • [29] Deep Gray Matter Atrophy in a Large Sample of Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis Patients
    Bergsland, Niels
    Dwyer, Michael G.
    Horakova, Dana
    Dolezal, Ondrej
    Havrdova, Eva
    Zivadinov, Robert
    NEUROLOGY, 2010, 74 (09) : A117 - A118
  • [30] Dimethyl Fumarate demonstrates Cost-effectiveness vs Teriflunomide in Treatment-naive Patients with Relapsing-remitting Multiple Sclerosis in Sweden
    Hernandez, L.
    Toro-Diaz, H.
    Cele, C.
    Harrington, A.
    Kinter, E.
    Lundqvist, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 138 - 138